其中，第一三共的明星产品Enhertu（德曲妥珠单抗）在2024财年前三季度全球销售额为4044亿日元（约26.82亿美元）。经查询，Enhertu在2024年Q1（即2023年财年Q4）销售额为1199亿日元。因此，按自然年计算，Enhertu在2 ...

Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology and international markets. Core operating profit rose 33% to ¥229 billion.

Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...

AstraZeneca and Daiichi Sankyo ’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...

AstraZeneca PLC on Thursday ended a strong year with better-than-expected fourth quarter earnings and said its pipeline would support further growth in 2025. The Cambridge-based pharmaceuticals firm ...

智通财经app获悉，1月27日，第一三共与阿斯利康(azn.us)宣布enhertu（德曲妥珠单抗）的补充生物制品许可申请（sbla）获fda批准，用于单药治疗在转移性 ...

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...

According to GlobalData’s Pharma Intelligence Center, the drug is projected to reach $13.9bn in sales by 2030. GlobalData is the parent company of Pharmaceutical Technology. Despite Enhertu’s ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

Enhertu (fam-trastuzumab deruxtecan-nxki) can cause side effects that range from mild to serious. More common side effects include hair loss, nausea, and vomiting. If Enhertu side effects become ...